Shorter or longer venetoclax with rituximab for relapsed chronic lymphocytic leukemia
Compares stopping or continuing venetoclax after 6 cycles in adults with relapsed chronic lymphocytic leukemia.
Key facts
- Who runs it
- Hemato-Oncologie voor Volwassenen Nederland (Hovon) Stichting
- Where
- 's-Gravenhage, 'S-Hertogenbosch, Alkmaar, Amstelveen, Arnhem, Beugen, Beverwijk, Breda, Delft, Deventer, Dirksland, Doetinchem, Dordrecht, Ede Gld, Emmen, Enschede, Geldrop, Geleen, Gorinchem, Gouda, Groningen, Harderwijk, Heerenveen, Helmond, Hoofddorp, Leeuwarden, Nieuwegein, Roermond, Roosendaal, Rotterdam, Terneuzen, Tiel, Tilburg, Uden, Utrecht, Zaandam, and Zwolle, NetherlandsSee the 39 sites
- Trial code
- Registry title
- HO182 CLL: Treatment of patients with chronic lymphocytic leukemia (CLL) with 6 cycles of rituximab in combination with 6 or 26 cycles of venetoclax upon recurrence of the disease after previous treatment
- Status
- Recruiting
- Phase
- Phase 3
- People taking part
- 456 people, planned
- Started
- 2 Sept 2026
- Expected to end
- 15 Jan 2032
- Type of study
- Interventional
- Record updated
- 28 August 2026
Who can take part
AI summary
From the trial's eligibility criteria. Machine-read from the registry text on this page, so it can be wrong. The registry text below and the trial team decide who can take part.
The trial is looking for adults whose chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma (SLL) came back or did not respond after at least one earlier drug treatment and who now need treatment.
- Age
- 18 years or older
- Sex
- All sexes can join.
- Disease stage
- CLL or SLL that came back or did not respond after at least one first treatment, and that needs treatment by IWCLL 2018 criteria. WHO performance status 0-3.
- Earlier treatment
- At least one earlier systemic first treatment. Venetoclax within 24 months before registration, or progression during earlier venetoclax, is not allowed.
- Biomarker or test result
- TP53 mutation status, del17p status (both tested after the last treatment) and IGHV mutation status must be tested.
Main reasons for not taking part
- Transformation of CLL (Richter's transformation)
- Central nervous system involvement
- Known HIV-positive
- Pregnant women and nursing mothers
- Severe heart, lung, nerve or mental illness (CTCAE grade III-IV)
The registry criteria, word for word
Show all 34 criteriaShow less
Who can take part
- Documented relapsed or refractory CLL or SLL following at least one systemic 1st-line treatment
- TP53 mutation status tested after last treatment
- Del17p mutation status tested after last treatment
- Patient is able and willing to adhere to the study visit schedule and other protocol requirements
- Written informed consent
- Patient is capable of giving informed consent
- Requiring treatment according to IWCLL 2018 criteria
- Age at least 18 years
- WHO performance status 0-3; stage 3 only if attributable to CLL/SLL
- Adequate BM function defined as: Hemoglobin (Hb) > 5.0 mmol/l, unless low Hb is directly attributable to CLL/SLL infiltration of the BM; Absolute neutrophil count (ANC) > 0.75 x 109/L (1,000/μL), unless low ANC is directly attributable to CLL/SLL infiltration of the BM; Platelet count > 30 x 109/L (30,000/μL), unless low platelets is directly attributable to CLL/SLL infiltration in the BM
- Estimated Glomerular Filtration Rate (eGFR) (MDRD) or estimated creatinine clearance (CrCl) ≥ 30ml/min (Cockcroft-Gault)
- Adequate liver function as indicated: serum aspartate transaminase (ASAT) and alanine transaminase (ALAT) ≤ 3.0 x upper limit of normal (ULN); bilirubin ≤ 1.5 x ULN (unless bilirubin rise is due to Gilbert's syndrome or controlled autoimmune hemolytic anemia)
- Negative serological testing for hepatitis B virus (Hepatitis B surface antigen (HBsAg) negative and hepatitis B core antibody (anti-HBc) negative) and hepatitis C virus (hepatitis C antibody). Patients who are positive for anti-HBc, HBsAg, or hepatitis C antibody must have a negative PCR result before enrollment. Those who are PCR positive will be excluded
- IGHV mutation status assessed at least once
Who cannot take part
- Active treatment with anti-neoplastic drugs in another clinical trial
- Patient received prior venetoclax treatment within 24 months of registration OR patient had progressed during previous venetoclax treatment
- Malignancies other than CLL/SLL currently requiring systemic therapy, not treated with curative intent, or showing signs of progression after curative treatment
- Concurrent severe and/or uncontrolled medical condition (e.g. uncontrolled diabetes, infection, hypertension, etc.)
- Previous participation in the HO139 CLL or HO140 CLL trial, and eligible for and willingness to participate in the HO159 CLL trial
- Any psychological, familial, sociological and geographical condition potentially hampering compliance with the study protocol and follow-up schedule
- Patient with a history of confirmed progressive multifocal leukoencephalopathy (PML)
- Known allergy to xanthine oxidase inhibitors and/or rasburicase
- History of drug-specific hypersensitivity or anaphylaxis to any study drug
- Severe cardiovascular disease (arrhythmias requiring chronic treatment, congestive heart failure or symptomatic ischemic heart disease) (CTCAE grade III-IV)
- Severe neurological or psychiatric disease (CTCAE grade III-IV)
- Active fungal, bacterial, and/or viral infection that requires systemic therapy
- Patient known to be HIV-positive
- Patient who has difficulty with or are unable to swallow oral medication, or have significant gastrointestinal disease that would limit absorption of oral medication
- Fertile men or women of childbearing potential unless: (1) surgically sterile or ≥ 2 years after the onset of menopause; (2) willing to use a highly effective contraceptive method such as oral contraceptives, intrauterine device or sexual abstinence during study treatment and for 30 days after last dose of venetoclax and/or 12 months after the last dose of rituximab
- Transformation of CLL (Richter’s transformation)
- Patient with central nervous system involvement
- Severe pulmonary dysfunction (CTCAE grade III-IV)
- Patient with Child Pugh C
- Pregnant women and nursing mothers
Where in Netherlands
- Haga Hospital's-Gravenhage, NetherlandsTaking people
- Jeroen Bosch Ziekenhuis Stichting'S-Hertogenbosch, NetherlandsTaking people
- Noordwest Ziekenhuisgroep StichtingAlkmaar, NetherlandsTaking people
- Ziekenhuis AmstellandAmstelveen, NetherlandsTaking people
- Rijnstate Ziekenhuis StichtingArnhem, NetherlandsTaking people
- Maasziekenhuis Pantein B.V.Beugen, NetherlandsTaking people
- Rode Kruis Ziekenhuis B.V.Beverwijk, NetherlandsTaking people
- Amphia HospitalBreda, NetherlandsTaking people
- Reinier de Graaf GroepDelft, NetherlandsTaking people
- Deventer ZiekenhuisDeventer, NetherlandsTaking people
- Het Van Weel-Bethesda ZiekenhuisDirksland, NetherlandsTaking people
- Slingeland ZiekenhuisDoetinchem, NetherlandsTaking people
- Albert Schweitzer ZiekenhuisDordrecht, NetherlandsTaking people
- Ziekenhuis Gelderse Vallei StichtingEde Gld, NetherlandsTaking people
- Treant Ziekenhuiszorg StichtingEmmen, NetherlandsTaking people
- Medisch Spectrum TwenteEnschede, NetherlandsTaking people
- Stichting St. Anna ZorggroepGeldrop, NetherlandsTaking people
- Zuyderland Medisch Centrum StichtingGeleen, NetherlandsTaking people
- Beatrix ZiekenhuisGorinchem, NetherlandsTaking people
- Groene Hart ZiekenhuisGouda, NetherlandsTaking people
- Martini Ziekenhuis StichtingGroningen, NetherlandsTaking people
- Ziekenhuis St JansdalHarderwijk, NetherlandsTaking people
- Frisius MCHeerenveen, NetherlandsTaking people
- Elkerliek ziekenhuisHelmond, NetherlandsTaking people
- Spaarne Gasthuis StichtingHoofddorp, NetherlandsTaking people
- Frisius MCLeeuwarden, NetherlandsTaking people
- St. Antonius ZiekenhuisNieuwegein, NetherlandsTaking people
- Laurentius Ziekenhuis RoermondRoermond, NetherlandsTaking people
- Bravis ZiekenhuisRoosendaal, NetherlandsTaking people
- Ikazia ZiekenhuisRotterdam, NetherlandsTaking people
- Maasstad Ziekenhuis StichtingRotterdam, NetherlandsTaking people
- ZorgSaam ZiekenhuisTerneuzen, NetherlandsTaking people
- Ziekenhuis RivierenlandTiel, NetherlandsTaking people
- Stichting Elisabeth-TweeSteden ZiekenhuisTilburg, NetherlandsTaking people
- Bernhoven B.V.Uden, NetherlandsTaking people
- Diakonessenhuis StichtingUtrecht, NetherlandsTaking people
- Universitair Medisch Centrum UtrechtUtrecht, NetherlandsTaking people
- Zaans Medisch Centrum StichtingZaandam, NetherlandsTaking people
- Isala Klinieken StichtingZwolle, NetherlandsTaking people
About the trial
What the trial wants to find out
To compare progression free survival (PFS) from the time of randomization between continuation of treatment with venetoclax for 20 cycles (Arm A) versus discontinuation of treatment (Arm B), in patients treated with 6 cycles Ven-R.
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Contact the study team: see the registry record
Print a page for my doctorData and sources
- Registry record
- Listed on the EU's official list of trials (CTIS).How to verify a trial in the registry
- Official title
- HOVON 182 CLL: Prospective randomized phase 3 study of treatment with rituximab (6 cycles) in combination with 6 or 26 cycles of venetoclax in patients with relapsed or refractory chronic lymphocytic leukemia RED RIVER CLL study: Reduced Duration Rituximab VEnetoclax in Relapsed/refractory CLL
- Plain-language title
- Shorter or longer venetoclax with rituximab for relapsed chronic lymphocytic leukemiaGenerated from the registry record. The registry title is the official one.
- AI summary
- From the trial's eligibility criteria. Read by machine on 9 November 2026.
- Record updated
- 28 August 2026